Genmab — Januar 2019
-
Fra JnJ CC transscript om Darzalex: U.S. grew 34% and continues to benefit from strong market growth and a 6-point increase in U.S. market share across all lines of therapy based on third quarter data. - Det tolker jeg som at dara har snuppet 6 %-point markedsandel i US.
-
Som svar på spørgsmål tidligere på aftenen vedr. royalty-satser. David svarede (efter Q3, tror jeg det var) på et spørgsmål fra en af bankanalytikerne om royalty-satser, med at citere de allerede kendte salgstal samt GENs fastholdte forventninger til royalty-indtægter og den gennemsnitlige $-kurs.. og sluttede med at sige man selv kunne "do the math".
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind